Relenza

  • Australian Government Stockpiles 1.6 million Courses of Relenza

    Biota Holdings has announced that the Australian government has purchased an additional 1.6 million courses of Relenza for the National Medical Stockpile to bolster supplies of antiviral drugs to treat pandemic influenza. The purchase cost is A$43 mi…

    Relenza | 08 June 2009

  • GSK: Dealing with Influenza A (H1N1)

    GlaxoSmithKline (GSK) is committed to supporting governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain. The company has developed a number of potential interventions which it believes…

    Relenza | 14 May 2009

  • Relenza: Sales in Q1

    Biota Holdings has received notification from GlaxoSmithKline (GSK) that Relenza sales were US$327.5 million and indicative royalties were US$22.9 million, for the three months ended 31 March 2009. Indicative royalties for the nine months to 31 Ma…

    Relenza | 04 May 2009

  • GSK Increases Imports of Relenza into Japan

    GlaxoSmithKline KK (GSK) has decided to increase the imports of its anti-influenza virus drug, Relenza (generic name: zanamivir hydrate) into Japan. Due to reports that the prevailing A/H1N1 influenza virus has become resistant to another anti-…

    Relenza | 24 February 2009

  • GSK Allows Simcere to Manufacture Relenza

    GlaxoSmithKline (GSK), Brenetford, West London, has given the green light to Chinese-based Simcere Pharmaceutical Group the right to produce generic copies of Relenza (zanamivir for inhalation) for developing countries. Under the terms of agreeme…

    Relenza | 23 November 2006